×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Dishman Carbogen Amcis Limited | 1002.8 | 26.7 | 628.6 | 0.17 | 4,418 | 37.2 |
| AARTI DRUGS LTD. | 5213.4 | 486.4 | 5209.6 | 5.33 | 4383 | 23.2 |
| INDRAPRASTHA MEDICAL CORP.LTD. | 3719.6 | 514.6 | 3650.6 | 5.61 | 4377 | 26.1 |
Dishman Carbogen Amcis Limited, with Security Code 540701, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 113.1 | 69.6 | 59.7 | 86.8 | 111.3 | 103.4 | 93.3 | 97.0 | 106.1 | 62.9 |
| Expenses | 106.8 | 74.6 | 62.6 | 83.7 | 99.7 | 88.5 | 79.9 | 74.1 | 85.5 | 59.4 |
| Operating Profit | 6.4 | -5.0 | -2.9 | 3.2 | 11.6 | 14.9 | 13.4 | 23.0 | 20.6 | 3.4 |
| OPM % | 5.61% | -7.22% | -4.89% | 3.65% | 10.4% | 14.41% | 14.36% | 23.66% | 19.43% | 5.46% |
| Other Income | 14.8 | 14.4 | 35.7 | 13.1 | -3.2 | 11.6 | 23.9 | -8.0 | 5.5 | 37.4 |
| Interest | 17.0 | 17.8 | 17.4 | 17.1 | 15.9 | 15.7 | 15.6 | 17.8 | 21.3 | 20.3 |
| Depreciation | 23.5 | 24.7 | 24.6 | 26.2 | 26.1 | 16.3 | 16.3 | 16.5 | 16.1 | 16.5 |
| Profit before tax | -19.3 | -33.0 | -6.2 | -27.1 | -33.6 | -5.6 | 5.4 | -19.3 | -11.3 | 4.1 |
| Tax % | -47.1% | -35.4% | -37.6% | -32.9% | -7.5% | 37.6% | 161.9% | -31.2% | 0% | 35.2% |
| Net Profit | -10.2 | -21.3 | -5.8 | -18.2 | -31.1 | -3.5 | 14.3 | -13.3 | -7.4 | 2.7 |
| EPS in Rs | -0.65 | -1.36 | -0.37 | -1.16 | -1.98 | -0.22 | 0.91 | -0.85 | 0 | 0.17 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 639.8 | 618.6 | 723.4 | 586.6 | 651.1 | 654.7 | 523.8 | 789.0 | 682.3 | 716.3 |
| Expenses | 525.9 | 567.1 | 601.5 | 525.7 | 610.0 | 592.0 | 494.8 | 641.9 | 542.2 | 563.6 |
| Operating Profit | 113.9 | 51.4 | 121.9 | 60.9 | 41.1 | 62.7 | 29.0 | 147.2 | 140.1 | 152.8 |
| OPM % | 17.8% | 8.32% | 16.85% | 10.37% | 6.31% | 9.57% | 5.53% | 18.65% | 20.54% | 21.32% |
| Other Income | 4.0 | -38.9 | 6.5 | 5.4 | 6.1 | 4.1 | -4.0 | 3.7 | 7.7 | -3.8 |
| Interest | 21.9 | 24.4 | 28.5 | 27.5 | 33.1 | 31.0 | 31.9 | 36.6 | 48.8 | 42.1 |
| Depreciation | 50.3 | 75.7 | 70.5 | 75.0 | 80.4 | 85.0 | 70.6 | 72.1 | 72.0 | 79.1 |
| Profit before tax | 48.1 | -42.0 | 29.5 | -33.2 | -66.3 | -46.1 | -72.1 | 45.1 | 25.0 | 39.5 |
| Tax % | 3% | -19.3% | -42.4% | 12.8% | -10% | 42.1% | 0% | 21.4% | 82.9% | 55.2% |
| Net Profit | 47.0 | -70.7 | 17.0 | -40.9 | -59.6 | -69.9 | -77.6 | 33.1 | 4.6 | 43.1 |
| EPS in Rs | 3 | -4.51 | 1.08 | -2.61 | -3.8 | -4.46 | -4.95 | 2.11 | 0.3 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -7% |
| 3 Years: | 9% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 19% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 27% |
| 3 Years: | 27% |
| 1 Year: | 28% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 6% |
| 3 Years: | 8% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 27% |
| 3 Years: | 27% |
| 1 Year: | 28% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|